Some patients report that the appetite-suppressing effects feel less pronounced after several months of treatment, though this experience is anecdotal and not well-characterized in the literature for tirzepatide specifically
Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Using available data, keeping the balance between excretion and overproduction of SUA is reasonable for prevention and management of gout
Furthermore, these treatments are not yet reimbursed by social security health system in France